

1 The importance of sustained compliance with physical distancing during
2 COVID-19 vaccination rollout: Supplementary materials

3 Alexandra Teslya, PhD^{*1}, Ganna Rozhnova, PhD^{1,2}, Thi Mui Pham¹, Daphne A van Wees,
4 PhD¹, Hendrik Nunner³, Noortje G Godijk¹, Martin Bootsma, PhD^{1,4}, and Mirjam E
5 Kretzschmar, PhD¹

6 ¹Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht
7 University, Utrecht, The Netherlands

8 ²BioISI—Biosystems & Integrative Sciences Institute, Faculdade de Ciências, Universidade de
9 Lisboa, Lisboa, Portugal

10 ³Faculty of Social Sciences, Utrecht University, Utrecht, The Netherlands

11 ⁴Mathematical Institute, Utrecht University, Utrecht, The Netherlands

*Corresponding author:

Dr. Alexandra Teslya
Julius Center for Health Sciences and Primary Care
University Medical Center Utrecht
P.O. Box 85500 Utrecht
The Netherlands
Email: a.i.teslya@umcutrecht.nl
Phone: +31 683890206

12 Contents

13	1 Compliance interventions for Alpha- and Delta-like variants	2
14	2 Additional physical distancing intervention during the vaccination rollout	3
15	3 Sensitivity analyses	7
16	3.1 Initial conditions	7
17	3.1.1 Compliant proportion of the population	8
18	3.1.2 Seroprevalence	10
19	3.1.3 Proportion of infectious cases	12
20	3.1.4 Proportion of exposed cases	14
21	3.2 Sensitivity analysis with respect to model parameters	16
22	3.2.1 Duration of latent and infectious periods	16
23	3.2.2 Contact rates of compliant and non-compliant individuals	18
24	3.2.3 Compliance acquisition and loss rates	20

25 1 Compliance interventions for Alpha- and Delta-like variants

26 We investigated the sensitivity of the cumulative number of new infections to the vaccination uptake rate and
27 vaccine efficacy in scenarios where the dominant SARS-CoV-2 virus variant is more transmissible than the original
28 variant, i.e. when either an Alpha-like or a Delta-like variant circulates (Figures 1a, 1b, 2a, and 2b). For both
29 variants, we also investigated the effects of interventions targeting compliance with physical distancing measures of
30 vaccinated and non-vaccinated individuals (Figures 1c-1h, 2c- 2h)).

31 For both strains, the qualitative dynamics observed when vaccination rollout is not accompanied by additional
32 interventions is similar to that of the original strain (Figures 1a, 1b, 2a, and 2b). More specifically, there is a
33 region for vaccine efficacy and vaccination uptake rate, where the cumulative number of infections exceeds the
34 number for the no-vaccination scenario three and six months after the start of the vaccination rollout. The highest
35 increase above the numbers seen for the no-vaccination scenario is expected for a high uptake rate and low vaccine
36 efficacy. Generally speaking, if the vaccination campaign is not accompanied by compliance-targeting interventions,
37 to achieve a better result than the no-vaccination scenario, the vaccine efficacy should exceed a certain threshold.
38 This threshold decreases with increasing vaccination uptake rate.

39 Similar to the original variant, the threshold vaccine efficacy is lower six months after the start of the vaccination
40 rollout than it is after three. However, for the more infectious strains, the difference in the threshold vaccine efficacy
41 is smaller than it was for the less infectious original variant. Finally, for both variants, in the regions where the

42 cumulative number of infections exceeds that of the no-vaccination scenario, this excess is larger than it was for the
43 original strain scenario (Figures 5a and 5b in the main text, Figures 1a, 1b, 2a, 2b).
44 For both variants, the intervention that targets compliance of non-vaccinated individuals, lowers the threshold
45 vaccine efficacy as compared to the vaccination rollout without compliance-targeting interventions (Figures 1c, 1d,
46 2c, 2d). Similar to the threshold for the original variant, this curve is lower at six months than at three months.
47 The intervention targeting compliance of vaccinated individuals lowers the threshold vaccine efficacy as compared
48 to the vaccination rollout without such intervention (Figures 5e and 5f in the main text, Figures 1e, 1f, 2e, 2f). For
49 both Alpha-like and Delta-like variants, six months after start of vaccination, the threshold vaccine efficacy required
50 to obtain improvements on the no-vaccination scenario has a more pronounced relationship with the vaccination
51 uptake rate than it does after three months. Similar to the scenario when the original variant circulates, the threshold
52 vaccine efficacy with low vaccination uptake rate is higher than when the vaccination rollout is not supplemented
53 by compliance targeting interventions interventions.
54 Finally, the combination of the two interventions, yields the best results for either variant. However, the threshold
55 vaccine efficacy is higher than for the original less-infectious variant (Figures 5g and 5h in the main text, Figures
56 1g, 1h, 2g, 2h).

57 **2 Additional physical distancing intervention during the vaccination** 58 **rollout**

59 We considered a scenario where if during the vaccination rollout the prevalence of new infectious cases exceeds
60 a certain threshold, the lockdown that we assumed was in place during the vaccination rollout becomes stricter,
61 further diminishing the average contact rate. Once the prevalence falls below the threshold, the lockdown is being
62 relaxed to its prior state. We refer to this intervention “dynamic” lockdown. We investigated the sensitivity of the
63 outputs to the threshold prevalence at which the lockdown is initiated. The original variant of the virus circulates.
64 The model parameters and initial conditions were fixed to the values used in the main text.
65 To perform the simulations we fixed the initial conditions and parameters to the values used in the main analyses.
66 We assume that the lockdown reduces the average contact rate from 5 to 3 individuals per day. This is comparable
67 to the number of contacts (3.5) residents of the Netherlands reported during the first weeks of the lockdown in
68 March 2020 reported by Backer et al [1]. We considered the threshold for the initiation (and the relaxation) of
69 the lockdown on the range of 50-1000 people. To assess the outcome of supplementing of the vaccination rollout
70 with strengthening of the lockdowns we considered the following outputs: the cumulative number of new infections
71 and the relative difference of the cumulative number of new infections as compared to the no-vaccination scenario
72 where the lockdown is strengthened and relaxed in the similar way. The summary of our simulations are presented
73 in Figure 3.




Figure 1: **Epidemic dynamics with and without interventions targeting compliance of vaccinated and non-vaccinated individuals.** An Alpha-like variant of the virus circulates. All panels show relative difference in cumulative number of new infections as compared to the no-vaccination scenario. **a** and **b** Vaccination rollout not supplemented with compliance interventions three and six months into the vaccination rollout, respectively. **c** and **d** Vaccination rollout supplemented with compliance interventions targeting non-vaccinated individuals three and six months into the vaccination rollout, respectively. **e** and **f** Vaccination rollout supplemented with compliance interventions targeting vaccinated individuals three and six months into the vaccination rollout, respectively. **g** and **h** Vaccination rollout supplemented with compliance interventions targeting both vaccinated and non-vaccinated individuals three and six months into the vaccination rollout, respectively. Magenta curves mark boundaries between parameter regions with different sign of the cumulative number of new infections. The scale of x-axes is not linear since vaccination coverage depends non-linearly on the vaccine uptake rate.

- 74 Both the cumulative number of new infections and the relative difference of the cumulative number as compared to
 75 the no-vaccination scenario is sensitive to the lockdown threshold value after six months of the vaccination rollout.
 76 In contrast, at three months after the vaccination rollout the threshold does not affect outcomes. After six months




Figure 2: **Epidemic dynamics with and without interventions targeting compliance of vaccinated and non-vaccinated individuals.** A Delta-like variant of the virus circulates. All panels show relative difference in cumulative number of new infections as compared to the no-vaccination scenario. **a** and **b** Vaccination rollout not supplemented with compliance interventions three and six months into the vaccination rollout, respectively. **c** and **d** Vaccination rollout supplemented with compliance interventions targeting non-vaccinated individuals three and six months into the vaccination rollout, respectively. **e** and **f** Vaccination rollout supplemented with compliance interventions targeting vaccinated individuals three and six months into the vaccination rollout, respectively. **g** and **h** Vaccination rollout supplemented with compliance interventions targeting both vaccinated and non-vaccinated individuals three and six months into the vaccination rollout, respectively. Magenta curves mark boundaries between parameter regions with different sign of the cumulative number of new infections. The scale of x-axes is not linear since vaccination coverage depends non-linearly on the vaccine uptake rate.

77 of the vaccination rollout, we observe that as the threshold for initiation (and relaxation) of the lockdown increases,
 78 the cumulative number of new infections increases as well. However, when the vaccination rollout is supplemented
 79 with “dynamic” lockdown, the cumulative number of new infections is expected to decrease below the level of

no-vaccination. It will decrease more for a fast vaccination rate than for a slow vaccination rate.




Figure 3: **Cumulative number of new infections for different thresholds of the initiation of lockdown restriction.** **a** and **b** show the cumulative number of new infections, presented as a percentage of the total population size. **c** and **d** show the relative difference in the number of new infections as compared to the no-vaccination scenario. **a** and **c** show the outputs for the slow vaccination uptake, **b** and **d** for the fast vaccination uptake.

We also investigated the improvements achieved by supplementing the vaccination rollout with a “dynamic” lockdown (Figure 4-5). We observe that the “dynamic” lockdown can lower the cumulative number of new infections almost two fold in the short term (three months after the start of the vaccination rollout) and more than that in the long term (six months after the start of the vaccination rollout) as compared with no-vaccination scenario. Supplementing the vaccination rollout with this intervention yields the best improvements on the no-vaccination scenario for a fast vaccination rate and a vaccine with high efficacy. On the other hand, when comparing the vaccination rollout with “dynamic” lockdown to one without, we observed that the largest improvements are gained for a fast vaccination rate and a vaccine with low efficacy. The lowest improvement are gained for a slow vaccination rate and a vaccine with high efficacy.




Figure 4: **Relative difference in the cumulative number of new infections as compared to the no-vaccination scenario for different thresholds of initiation of lockdown strengthening.** Difference in the cumulative number of new infections as compared to the no-vaccination scenario after **a** and **c** three months; **b** and **d** six months of the vaccination rollout. **a** and **b** Results for a lockdown threshold of 50 individuals, **c** and **d** for a lockdown threshold of 500 individuals.

90 3 Sensitivity analyses

91 In this section we report results on the sensitivity of the epidemic dynamics during vaccination rollout to assumptions
 92 about initial conditions and parameter values. We considered the cumulative number of new infections three and
 93 six months after the start of the vaccination rollout. We used the absolute size of the cumulative number, presented
 94 as percentage of the total population size and the relative difference with respect to the cumulative number of
 95 new infections relative to the no-vaccination scenario, presented as percentage. The original variant of the virus
 96 circulates and no interventions targeting compliance are in place.

97 3.1 Initial conditions

98 First, we investigated sensitivity of the results to the initial sizes of the compartments at the start of the simulation.
 99 More specifically, we varied the initial numbers of the compliant, exposed, infectious, and recovered populations
 100 in the ranges of 20-90%, 0.1-1% 0.01-1%, and 5-20%, respectively. The model parameters were fixed to the values




Figure 5: **Relative difference in the cumulative number of new infections as compared to the vaccination rollout without additional interventions for different thresholds of initiation of lockdown strengthening.** Difference in the cumulative number of new infections as compared to the vaccination rollout without additional interventions after **a** and **c** three months; **b** and **d** six months of the vaccination rollout. **a** and **b** Results for a lockdown threshold of 50 individuals, **c** and **d** for a lockdown threshold of 500 individuals.

101 used in the main text, with vaccine efficacy in preventing the acquisition of the infection set at 60%. The results
 102 are presented for slow and fast vaccination rates (see the main text for the definition).

103 3.1.1 Compliant proportion of the population

104 In the main analysis, we calibrated the percentage of the population compliant with physical distancing measures
 105 at the start of the vaccination rollout using reported compliance of 65% with a specific measure (keeping 1.5m
 106 distance) in the Netherlands on the week of November 11-17, 2020 [2]. We used this number as a proxy to being
 107 compliant to recommended physical distancing measures, and subsequently substantially reducing contact rates.
 108 In what follows, we vary the initial percentage in a range of 20 – 90% for the percentage of the population that
 109 complies with physical distancing measures, and investigate the effect of the initial percentage of compliance on
 110 the outputs (Figure 6). The sizes of susceptible, exposed, infectious and recovered compartments are fixed to the
 111 values used in the main analysis.

112 The model predicts that the cumulative number of new infections is lower for higher percentage of the initial




Figure 6: **Cumulative number of new infections for different percentages of compliant individuals at the start of the vaccination rollout.** **a** and **b** show cumulative number of new infections versus percentage of compliant individuals at the start of the vaccination rollout. The results are presented as a percentage of the total population. **c** and **d** show relative difference in the cumulative number of new infections relative to the baseline no-vaccination values versus percentage of compliant individuals at the start of the vaccination rollout. The results are presented as a percentage of the cumulative number of new infections in the no-vaccination scenario. The original variant is circulating. The results are presented for slow (**a** and **c**) and fast (**b** and **d**) vaccination rates.

113 proportion of compliant individuals. This is observed in the short term (three months following the vaccination
 114 rollout, Figure 6a) and in the long term (six months following the vaccination rollout, Figure 6b).

115 The model predicts that the excess of infections reported in the main analysis is preserved for the range of percentages
 116 of compliant individuals that we considered (Figure 6c and 6d). This percentage is an increases as the initial
 117 proportion of compliant individuals increases and is higher for a fast vaccination rollout following three and six
 118 of the vaccination rollout. However, variation of relative excess of the infections as the percentage of compliant
 119 individuals change does not exceed 3%. This indicates the outputs are not sensitive to the variation in the initial

120 number of compliant individuals.

121 **3.1.2 Seroprevalence**

122 We defined seroprevalence as the proportion of the population that has been infected with SARS-CoV-2 and is
123 immune to a new infection at the start of the simulations. In the main analysis we calibrated the model to a
124 seroprevalence of 8%, which is between what was measured in the Netherlands in September/October 2020 [3]
125 and in February 2021 [4]. We explored the sensitivity of the outputs to the initial value of seroprevalence, by
126 varying the initial seroprevalence in the range of 5-20% (Figure 7). We kept the sizes of the exposed and infectious
127 compartments fixed to the values used in the main analysis. To preserve the constant size of the total population,
128 we adjusted the size of the susceptible compartment accordingly.




Figure 7: **Cumulative number of new infections for different seroprevalence at the start of the vaccination rollout.** **a** and **b** show the cumulative number of new infections versus percentage of recovered individuals at the start of the vaccination rollout. The results are presented as a percentage of the total population. **c** and **d** show relative difference in the cumulative number of new infections relative to the baseline no-vaccination values versus percentage of recovered individuals at the start of the vaccination rollout. The results are presented as a percentage of the cumulative number of new infections in the no-vaccination scenario. The original variant is circulating. The results are presented for slow (**a** and **c**) and fast (**b** and **d**) vaccination rates.

129 The model predicts that the cumulative number of new infections is lower for higher seroprevalence. This is
 130 observed in the short term (three months following the vaccination rollout, Figure 7a) and in the long term (six
 131 months following the vaccination rollout, Figure 7b).

132 Our simulations show that the excess infections seen in the main analysis is preserved for a wide range of sero-
 133 prevalence values (Figure 7c and 7d). For a fast vaccination rate the relative excess is significantly larger than for

134 a slow vaccination rate, both in the long and in the short term. For both slow and fast vaccination, the relative
135 excess of infections is decreasing as the percentage of recovered individuals at the start of the vaccination rollout
136 increases. Noteworthy, this decrease is much faster for the fast vaccination rollout than for the slow one, making
137 the dynamics very sensitive to the value of seroprevalence at the start of the vaccination rollout.

138 **3.1.3 Proportion of infectious cases**

139 In the main analysis we set the number of infectious individuals to be equal to 112,435 individuals (0.66% of the
140 population size of the Netherlands) as was estimated by RIVM for the week November 11-17. We explored the
141 sensitivity of the outputs to the initial value of the number of infectious cases, which we sampled from the interval
142 0.1-1% (Figures 8). We kept the sizes of the exposed and recovered compartments fixed to the values used in
143 the main analysis. To preserve the constant size of the total population, we adjusted the size of the susceptible
144 compartment accordingly.

145 The model predicts that the cumulative number of new infections increases as the number of infectious individuals
146 at the start of the vaccination rollout increases. This is observed in the short term (three months following the
147 vaccination rollout, Figure 8a) and in the long term (six months following the vaccination rollout, Figure 8b).




Figure 8: **Cumulative number of new infections for different percentages of infectious individuals at the start of the vaccination rollout.** **a** and **b** show the cumulative number of new infections versus percentage of recovered individuals at the start of the vaccination rollout. The results are presented as a percentage of the total population. **c** and **d** show relative difference in the cumulative number of new infections relative to the baseline no-vaccination values versus percentage of infectious individuals at the start of the vaccination rollout. The results are presented as a percentage of the cumulative number of new infections in the no-vaccination scenario. The original variant is circulating. The results are presented for slow (**a** and **c**) and fast (**b** and **d**) vaccination rates.

148 Our simulations show that the excess infections seen in the main analysis is preserved for a wide range of initial
 149 infectious individuals values (Figure 8c and 8d). For slow vaccination rollout, the excess is decreasing with increasing
 150 number of infectious individuals, both in the long term and in the short term. In contrast, for a fast vaccination
 151 rate, for a low initial initial number of infectious individuals, the excess increases, while for a higher number it
 152 decreases. This relationship is present both in the short term (three months after the start of the vaccination
 153 rollout) and in the long term (six months after the start of the vaccination rollout). We note that changes in the

154 relative excess of infections in the range of the number of infectious individuals that we considered does not exceed
155 3%, thus indicating a low sensitivity of the outputs to variations in this initial condition.

156 **3.1.4 Proportion of exposed cases**

157 In the main analysis we set number of infectious of exposed individuals to be equal to 64249 individuals (0.38% of
158 the population size of the Netherlands) which we calculate using the approximation to the total number of infectious
159 cases made by RIVM for the week November 11-1. We explored the impact of the initial proportion of exposed cases
160 on epidemic and compliance dynamics by sampling the prevalence in the range of 0.1-1% of the total population
161 (Figures 8). As the size of the exposed compartment changed, we kept the size of the infectious and recovered
162 compartments fixed to the values used in the main analysis. To preserve the constant size of the total population,
163 we adjusted the size of the susceptible compartment.

164 The model predicts that the cumulative number of new infections increases as the proportion of exposed cases at the
165 start of the vaccination rollout increases. This is observed in the short term (three months following the vaccination
166 rollout, Figure 9a) and in the long term (six months following the vaccination rollout, Figure 9b).




Figure 9: **Cumulative number of new infections for different percentages of exposed individuals at the start of the vaccination rollout.** **a** and **b** show the cumulative number of new infections versus percentage of recovered individuals at the start of the vaccination rollout. The results are presented as a percentage of the total population. **c** and **d** show relative difference in the cumulative number of new infections relative to the baseline no-vaccination values versus percentage of exposed individuals at the start of the vaccination rollout. The results are presented as a percentage of the cumulative number of new infections in the no-vaccination scenario. The original variant is circulating. The results are presented for slow (**a** and **c**) and fast (**b** and **d**) vaccination rates.

167 Our simulations indicate that the excess of the new infections as compared to the baseline no-vaccination scenario is
 168 preserved for all the values of percentage of exposed individuals that we have sampled. We also observe a relatively
 169 low sensitivity of the relative excess of new infections to changes in the initial percentage of exposed individuals
 170 (Figures 9c and 9d) when the vaccination uptake is low. In this case, the relative excess of the cumulative number of
 171 infections remains on approximately the same level on the whole range that we considered. On the other hand, given
 172 the fast vaccination rate, we observe that the relative excess increases as the initial proportion of exposed individuals
 173 increases and that the outputs corresponding to endpoints of the exposed percentage interval are approximately 5%

174 apart, both for three and six months.

175 **3.2 Sensitivity analysis with respect to model parameters**

176 In this section we report results of the investigation of sensitivity of the outputs of the model to the chosen values
177 of parameters. The outputs are the cumulative number of new infections three and six months after the vaccination
178 rollout started presented as the percentage from the total population size. The initial conditions are fixed to the
179 values that were used in the main text. The parameters that we consider are 1. the duration of the exposed period
180 ($1/\alpha$); 2. the duration of the infectious period ($1/\gamma$); 3. the average contact rate of non-compliant individuals (c);
181 4. the average contact rate of compliant individuals (cr_1); 5. rate of moving to compliant state (δ); 6. the duration
182 of compliant state when there is no vaccination (μ_0). We look at the effects of variation parameters in pairs, fixing
183 the rest of the parameters to be equal to the values used in the main analysis. Similarly, the initial conditions are
184 fixed to be equal to the values used in the main analysis. The results are presented for slow and fast vaccination
185 rates (see the main text for the definition).

186 **3.2.1 Duration of latent and infectious periods**

187 In this section we consider the sensitivity of the outputs to the selected values of the duration of the exposed
188 period ($1/\alpha$) and the duration of the infectious period ($1/\gamma$). In the main text they are fixed to be 4 and 7 days,
189 respectively. Here we sample $1/\alpha$ in the range of 2-6 days and $1/\gamma$ in the range of 5-9 days (Figure 10).

190 We observe that the epidemic burden increases as the infectious period increases, such that when the vaccination
191 rate is fast the increase in the cumulative number of new infections is higher than when the vaccination rate is slow.
192 On the other hand, we observe that when the length of the exposed period has very little bearing on the cumulative
193 number of new infections, as compared to the duration of infectious period.




Figure 10: **Cumulative number of new infections depending on duration of exposed and infectious periods.** **a** and **b** show the cumulative number of infections three months after the start of vaccination rollout. **c** and **d** show the cumulative number of infections six months after the start of vaccination rollout. **a** and **c** show these quantities for the slow vaccination uptake, **b** and **d** for the fast vaccination uptake.

194 Our results indicate the relative excess of infections as compared to the no-vaccination scenario is preserved through-
 195 out the ranges that we have considered (Figure 11). However, the sensitivity of the magnitude of the excess to
 196 variation in the duration of exposed and infectious periods depend on the vaccination uptake rate. If the vacci-
 197 nation rate is slow, than the largest change in the excess that we have measured across the parameter range was
 198 approximately equal to 13%. For the vast vaccination rate, especially at a later time the expected excess ranged
 199 from almost 14% to 99%. The excess in the cumulative number of infections is increasing as either the duration of
 200 the infectious period and of the duration of the exposed period increases. However, the changes are more drastic
 201 for the former than for the latter.




Figure 11: **Relative difference in the cumulative number of new infections compared to the no-vaccination scenario depending on duration of exposed and infectious periods.** **a** and **b** show relative difference in the cumulative number of new infections three months after the start of vaccination rollout; **c** and **d** show the same quantity six months after the start of vaccination rollout. **a** and **c** slow vaccination uptake; **b** and **d** fast vaccination uptake.

3.2.2 Contact rates of compliant and non-compliant individuals

We considered the sensitivity of the outputs to the contact rates of compliant individuals c and the ratio of contact rates of compliant and non-compliant individuals r_1 . In the main text these parameters were fixed at 8.8 per day and 0.34, respectively. Here we vary c in the range of 0.5-15 per day and r_1 in the range of 0.01-1 (Figure 12). The effective reproduction number changes as c and r_1 change.

We observe that both parameters have a strong influence on the cumulative number of infections, both in the short term (after three months of the vaccination rollout) and in the long term (after six months of the vaccination rollout). At both these time points, fast vaccination is characterized by significantly lower cumulative number of new infections, both in the short term and in the long term.




Figure 12: **Cumulative number of new infections for different depending on contact rates of compliant and non-compliant individuals.** **a** and **b** show the cumulative number of infections three months after the start of vaccination rollout; **c** and **d** six months after the start of vaccination rollout. **a** and **c** show these quantities for the slow vaccination uptake, **b** and **d** fast vaccination uptake.

211 Our simulations shown in Figure 13 indicate that a possible excess in number of infections as compared to the no-
 212 vaccination scenario is highly sensitive to the contact rates of compliant and non-compliant individuals. Generally,
 213 we expect the cumulative number of infections to exceed that of the no-vaccination scenario if there is a significant
 214 difference between contact rates of compliant and non-compliant individuals. The largest increases in the cumulative
 215 number of infections in the first months of the vaccination rollout are expected when the contact rate of non-
 216 compliant individuals is close to the pre-pandemic levels and the contact rate of compliant individuals is significantly
 217 lower.

Three months




Figure 13: **Relative difference in the cumulative number of new infections compared to the no-vaccination scenario depending on contact rates of compliant and non-compliant individuals.** **a** and **b** show the relative difference in the cumulative number of new infections compared to the no-vaccination scenario three months after the start of vaccination rollout; **c** and **d** show the same quantity six months after the start of vaccination rollout. **a** and **c** show these quantities for the slow vaccination uptake, **b** and **d** fast vaccination uptake.

218 3.2.3 Compliance acquisition and loss rates

219 We considered the sensitivity of the outputs to the rate of moving to the compliant state (δ), and to the duration
 220 of compliance when there is no vaccination ($1/mu_0$). In the main text we set the compliance duration when there
 221 is no vaccination to 30 days. This is an assumed value and here we test the effect of shorter duration of compliance
 222 on epidemic dynamics. We consider a range of compliance duration between 7 and 30 days. In the main text we
 223 fixed the rate of moving to the compliant state to 4×10^{-5} per day. Here, we considered the range of 10^{-6} - 10^{-4} .
 224 The results are summarized in Figure 14

225 We observe that the outputs are sensitive to the values of both parameters with the cumulative number of infections
 226 decreasing as the rate of moving to compliant state increases and duration of compliant state. However, this

227 relationship is more apparent six month after the start of the vaccination rollout than after three months.





Figure 14: **Cumulative number of new infections depending on the rate of moving to the compliant state and compliance duration.** **a** and **b** show the cumulative number of infections three months after the start of vaccination rollout; **c** and **d** six months after the start of vaccination rollout. **a** and **c** show these quantities for the slow vaccination uptake, **b** and **d** fast vaccination uptake.

228 Our simulations indicate that the occurrence of excess infections relative to the no-vaccination scenario during the
229 first months of the vaccination rollout is sensitive to changes in the rate of moving to the compliant state and the
230 duration of the compliant state after the first three months of vaccination. The excess of infections is observed for
231 high rates of moving to the compliant state and long duration of compliance. After six months of vaccination there
232 was an excess of infections for the whole range of parameters that we considered.

Three months



Six months




Figure 15: **Relative difference in the cumulative number of new infections compared to the no-vaccination scenario depending on transition rate to compliance and compliance duration.** **a** and **b** show the relative difference in the cumulative number of new infections compared to the no-vaccination scenario three months after the start of vaccination rollout; **c** and **d** six months after the start of vaccination rollout. **a** and **c** show these quantities for the slow vaccination uptake, **b** and **d** fast vaccination uptake.

References

- [1] JA Backer, L Mollema, ERA Vos, D Klinkenberg, FRM van der Klis, HE de Melker, et al. Impact of physical distancing measures against COVID-19 on contacts and mixing patterns: repeated cross-sectional surveys, the Netherlands, 2016-17, April 2020 and June 2020. *Eurosurveillance*, 26(8):2000994, 2021. doi: 10.2807/1560-7917.ES.2021.26.8.2000994. URL <https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.8.2000994>.

- 239 [2] The National Institute for Public Health and the Environment (RIVM). Research on behavioural rules and well-
240 being: round 8, 2021. URL [https://www.rivm.nl/en/novel-coronavirus-covid-19/research/behaviour/
241 -behavioural-rules-and-well-being-round-8](https://www.rivm.nl/en/novel-coronavirus-covid-19/research/behaviour/-behavioural-rules-and-well-being-round-8). Accessed February 25, 2021.
- 242 [3] ERA Vos, G den Hartog, RM Schepp, P Kaaijk, J van Vliet, K Helm, et al. Nationwide seroprevalence of
243 SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first
244 epidemic wave. *Journal of Epidemiology & Community Health*, 2020. doi: 10.1136/jech-2020-215678. URL
245 <https://jech.bmj.com/content/early/2020/11/28/jech-2020-215678>.
- 246 [4] The National Institute for Public Health and the Environment (RIVM). PIENTER Corona Studie: Resultaten,
247 2021. URL <https://www.rivm.nl/pienter-corona-studie/resultaten>. Accessed August 1, 2021.